# UNITED STATES <br> SECURITIES AND EXCHANGE COMMISSION <br> Washington, D.C. 20549 

$\qquad$

## FORM 8-K

$\qquad$
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3, 2020

## QUANEX BUILDING PRODUCTS CORPORATION

(Exact name of registrant as specified in its charter)

## Delaware

(State or Other Jurisdiction of Incorporation)
001-33913
(Commission File Number)

## 26-1561397

(I.R.S. Employer Identification No.)

> 1800 West Loop South, Suite 1500
> Houston, Texas 77027
> (Address of Principal Executive Offices) (Zip Code)
> (713) 961-4600
> (Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class $\quad$ Trading Symbol(s) $\quad$ Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12 b - 2 of the Securities Exchange Act of 1934 ( $\$ 240.12 b-2$ of this chapter).
Emerging growth company $\square$
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 2.02. Results of Operations and Financial Condition.

On September 3, 2020, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

## Item 7.01. Regulation FD Disclosure.

On September 3, 2020, the Registrant issued a press release announcing that the Board had declared a quarterly cash dividend of $\$ 0.08$ per share of common stock, payable on September 30, 2020, to shareholders of record on September 16, 2020. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

## Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated September 3, 2020
Exhibit 104. Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Quanex Building Products Corporation

# Quanex Building Products Announces Third Quarter 2020 Results and Provides Updated Full Year 2020 Guidance 

Balance Sheet \& Liquidity Remain Strong<br>Repaid $\$ 78$ Million of Bank Debt<br>Over 50\% Increase in Cash Provided by Operations<br>Margin Expansion Realized in EU Fenestration Segment<br>Management Remains Optimistic on Recovery

HOUSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Quanex Building Products Corporation (NYSE:NX) ("Quanex" or the "Company") today announced its results for the three months ended July 31, 2020.

The Company reported the following selected financial results:

|  | Three Months Ended July 31, |  | Nine Months Ended July 31, |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2020 | 2019 | 2020 | 2019 |
| Net Sales | \$212.1 | \$238.5 | \$596.2 | \$653.5 |
| Gross Margin | \$49.7 | \$57.1 | \$126.6 | \$142.2 |
| Gross Margin \% | 23.4\% | 23.9\% | 21.2\% | 21.8\% |
| Net Income (Loss) | \$10.8 | \$11.8 | \$16.3 | (\$15.8) |
| Diluted EPS | \$0.33 | \$0.36 | \$0.50 | (\$0.48) |
| Adjusted Net Income | \$11.1 | \$13.7 | \$18.7 | \$17.8 |
| Adjusted Diluted EPS | \$0.34 | \$0.41 | \$0.57 | \$0.54 |
| Adjusted EBITDA | \$27.7 | \$32.8 | \$65.2 | \$68.2 |
| Adjusted EBITDA Margin \% | 13.1\% | 13.7\% | 10.9\% | 10.4\% |
| Cash Provided by Operating Activities | \$45.1 | \$29.9 | \$47.6 | \$30.0 |
| Free Cash Flow | \$40.7 | \$25.9 | \$26.9 | \$13.1 |

(See Non-GAAP Terminology Definitions and Disclaimers section, Non-GAAP Financial Measure Disclosure table Selected Segment Data table and Free Cash Flow Reconciliation table for additional information)

George Wilson, President and Chief Executive Officer, stated, "Despite the impact from the COVID-19 pandemic, third quarter results proved better than we expected and exceeded the guidance we provided on our last earnings call. Volumes increased steadily throughout the quarter, especially in Europe, and we remain optimistic on the recovery. We continue to focus on managing working capital and generating cash. As a result, we realized an increase of over $50 \%$ in cash provided by operating activities as compared to the same period of 2019 . We were also able to repay $\$ 78$ million of bank debt during the quarter, $\$ 50$ million of which was drawn as a precautionary measure in response to the pandemic, and our leverage ratio of Net Debt to LTM Adjusted EBITDA improved to a level below where we ended fiscal 2019. We have worked tirelessly over the past several years to make sure we have a flexible capital structure and a strong balance sheet, which has left our Company well positioned to navigate the challenges presented by the COVID-19 pandemic."

Consistent with most companies, we withdrew guidance for fiscal 2020 in March due to the uncertainty surrounding the COVID-19 pandemic. Our results have been negatively impacted by the pandemic; however, we continue to be positively surprised by the pace at which demand for our products has returned. As such, we are now comfortable providing full year 2020 guidance of $\$ 832$ million to $\$ 837$ million in net sales and $\$ 97$ million to $\$ 102$ million in Adjusted EBITDA*. (See Non-GAAP Terminology Definitions and Disclaimers section for additional information)
*When Quanex provides expectations for Adjusted EBITDA on a forward-looking basis, a reconciliation of the differences between the nonGAAP expectations and corresponding GAAP measures is generally not available without unreasonable effort. Certain items required for such a reconciliation are outside of the Company's control and/or cannot be reasonably predicted or estimated, such as the provision for income taxes.

## Third Quarter 2020 Results Summary

The decrease in net sales during the third quarter of 2020 was largely attributable to softer demand related to the COVID-19 pandemic. The Company's two manufacturing facilities in the UK were shut down in compliance with government orders on March 25,2020 , and manufacturing operations at those plants did not restart until mid-to-late May. However, volume across all segments increased significantly in June and net sales in July exceeded prior year on a consolidated basis. (See Sales Analysis table for additional information)

The decrease in reported earnings was primarily due to reduced operating leverage as a result of softer volumes related to the pandemic.

## Balance Sheet \& Liquidity Update

As of July 31, 2020, the Company's leverage ratio of Net Debt to LTM Adjusted EBITDA improved to 1.1x. Quanex expects to exit fiscal 2020 with a leverage ratio of Net Debt to LTM Adjusted EBITDA at or below 1.0x. (See Non-GAAP Terminology Definitions and Disclaimers section for additional information)

The Company's liquidity increased to $\$ 223.2$ million as of July 31,2020 , consisting of $\$ 41.1$ million in cash on hand plus availability under its Senior Secured Revolving Credit Facility due 2023, less letters of credit outstanding.

## Share Repurchases

Quanex's Board of Directors authorized a $\$ 60$ million share repurchase program in September of 2018. Repurchases under this program will be made in open market transactions or privately negotiated transactions, subject to market conditions, applicable legal requirements and other relevant factors. The program does not have an expiration date or a limit on the number of shares that may be repurchased. The Company did not
repurchase any shares of common stock during the three months ended July 31, 2020. As of July 31, 2020, approximately $\$ 11.7$ million remained under the existing share repurchase authorization.

## Recent Events

Quanex's Board of Directors declared a quarterly cash dividend of $\$ 0.08$ per share on the Company's common stock, payable September 30, 2020, to shareholders of record on September 16, 2020.

## Conference Call and Webcast Information

The Company has scheduled a conference call for Friday, September 4, 2020, at 11:00 a.m. ET (10:00 a.m. CT). To participate in the conference call dial (877) 388-2139 for domestic callers and (541) 797-2983 for international callers, in both cases using the conference passcode 6194308 , and ask for the Quanex call a few minutes prior to the start time. A link to the live audio webcast will also be available on the Company's website at http://www.quanex.com in the Investors section under Presentations \& Events. A telephonic replay of the call will be available approximately two hours after the live broadcast ends and will be accessible through September 11, 2020. To access the replay dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers, in both cases referencing conference passcode 6194308.

## About Quanex

Quanex Building Products Corporation is an industry-leading manufacturer of components sold to Original Equipment Manufacturers (OEMs) in the building products industry. Quanex designs and produces energy-efficient fenestration products in addition to kitchen and bath cabinet components. For more information contact Scott Zuehlke, Senior Vice President, Chief Financial Officer \& Treasurer, at 713-877-5327 or scott.zuehlke@quanex.com.

## Non-GAAP Terminology Definitions and Disclaimers

Adjusted Net Income (Loss) (defined as net income further adjusted to exclude purchase price accounting inventory step-ups, transaction costs, certain severance charges, gain/loss on the sale of certain fixed assets, restructuring charges, asset impairment charges, other net adjustments related to foreign currency transaction gain/loss and effective tax rates reflecting impacts of adjustments on a with and without basis) and Adjusted EPS are non-GAAP financial measures that Quanex believes provide a consistent basis for comparison between periods and more accurately reflects operational performance, as they are not influenced by certain income or expense items not affecting ongoing operations. EBITDA (defined as net income or loss before interest, taxes, depreciation and amortization and other, net) and Adjusted EBITDA (defined as EBITDA further adjusted to exclude purchase price accounting inventory step-ups, transaction costs, certain severance charges, gain/loss on the sale of certain fixed assets, restructuring charges and asset impairment charges) are non-GAAP financial measures that the Company uses to measure operational performance and assist with financial decision-making. The leverage ratio of Net Debt to LTM Adjusted EBITDA is a financial measure that the Company believes is useful to investors and financial analysts in evaluating Quanex's leverage. In addition, with certain limited adjustments, this leverage ratio is the basis for a key covenant in the Company's credit agreement. Free Cash Flow is a non-GAAP measure calculated using cash provided by operating activities less capital expenditures. Free Cash Flow is measured before application of certain contractual commitments (including capital lease obligations), and accordingly is not a true measure of Quanex's residual cash flow available for discretionary expenditures. The Company believes that the presented non-GAAP measures provide a consistent basis for comparison between periods, and will assist investors in understanding Quanex's financial performance when comparing results to other investment opportunities. The presented non-GAAP measures may not be the same as those used by other companies. The Company does not intend for this information to be considered in isolation or as a substitute for other measures prepared in accordance with U.S. GAAP.

## Forward Looking Statements

Statements that use the words "estimated," "expect," "could," "should," "believe," "will," "might," or similar words reflecting future expectations or beliefs are forward-looking statements. The forward-looking statements include, but are not limited to, the following: impacts from public health issues (including pandemics, such as the recent COVID-19 pandemic) on the economy and the demand for Quanex's products, the Company's future operating results, future financial condition, future uses of cash and other expenditures, expenses and tax rates, expectations relating to Quanex's industry, and the Company's future growth, including any guidance discussed in this press release. The statements and guidance set forth in this release are based on current expectations. Actual results or events may differ materially from this release. For a complete discussion of factors that may affect Quanex's future performance, please refer to the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2019, and the Company's Quarterly Reports on Form 10-Q under the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors". Any forward-looking statements in this press release are made as of the date hereof, and Quanex undertakes no obligation to update or revise any forward-looking statements to reflect new information or events.

## QUANEX BUILDING PRODUCTS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(In thousands, except per share data)
(Unaudited)

Net sales
Cost of sales
Selling, general and administrative
Restructuring charges
Depreciation and amortization
Asset impairment charges
Operating income (loss)
Interest expense

| Three Months Ended July 31, |  |  |  | Nine Months Ended July 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2020 |  | 2019 |  | 2020 |  | 2019 |  |
| \$ | 212,096 | \$ | 238,461 | \$ | 596,168 | \$ | 653,472 |
|  | 162,427 |  | 181,357 |  | 469,586 |  | 511,292 |
|  | 21,973 |  | 25,718 |  | 62,818 |  | 77,466 |
|  | 73 |  | 94 |  | 477 |  | 281 |
|  | 11,060 |  | 12,182 |  | 35,851 |  | 37,158 |
|  | - |  | - |  | - |  | 29,978 |
|  | 16,563 |  | 19,110 |  | 27,436 |  | $(2,703)$ |
|  | $(1,165)$ |  | $(2,570)$ |  | $(4,310)$ |  | $(7,614)$ |
|  | (220) |  | 259 |  | 116 |  | 461 |
|  | 15,178 |  | 16,799 |  | 23,242 |  | $(9,856)$ |

Income tax expense
Net income (loss)

Earnings (loss) per common share, basic
Earnings (loss) per common share, diluted
Weighted average common shares outstanding:

## Basic

Diluted
Cash dividends per share

|  | $(4,345)$ |  | $(4,958)$ |  | $(6,898)$ |  | $(5,926)$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| \$ | 10,833 | \$ | 11,841 | \$ | 16,344 | \$ | $(15,782)$ |
| \$ | 0.33 | \$ | 0.36 | \$ | 0.50 | \$ | (0.48) |
| \$ | 0.33 | \$ | 0.36 | \$ | 0.50 | \$ | (0.48) |
|  | 32,610 |  | 32,899 |  | 32,716 |  | 32,984 |
|  | 32,739 |  | 33,162 |  | 32,845 |  | 32,984 |
| \$ | 0.08 | \$ | 0.08 | \$ | 0.24 | \$ | 0.24 |

QUANEX BUILDING PRODUCTS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)

## ASSETS

Current assets:
Cash and cash equivalents
Accounts receivable, net
Inventories, net
Prepaid and other current assets Total current assets
Property, plant and equipment, net
Operating lease right-of-use assets
Goodwill
Intangible assets, net
Other assets
Total assets

## LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable
Accrued liabilities
Income taxes payable
Current maturities of long-term debt
Current operating lease liabilities
Total current liabilities
Long-term debt
Noncurrent operating lease liabilities
Deferred pension and postretirement benefits
Deferred income taxes
Other liabilities Total liabilities
Stockholders' equity:
Common stock
Additional paid-in-capital
Retained earnings
Accumulated other comprehensive loss
Treasury stock at cost
Total stockholders' equity
Total liabilities and stockholders' equity

July 31, 2020

| July 31, 2020 |  | October 31, 2019 |  |
| :---: | :---: | :---: | :---: |
| \$ | 41,073 | \$ | 30,868 |
|  | 84,479 |  | 82,946 |
|  | 63,939 |  | 67,159 |
|  | 7,930 |  | 9,353 |
|  | 197,421 |  | 190,326 |
|  | 186,830 |  | 193,600 |
|  | 49,644 |  | - |
|  | 146,932 |  | 145,563 |
|  | 96,957 |  | 107,297 |
|  | 9,007 |  | 8,324 |
| \$ | 686,791 | \$ | 645,110 |

Asset impairment charge
Other, net
Changes in assets and liabilities:
(Increase) decrease in accounts receivable

|  | - | 29,978 |
| :---: | :---: | :---: |
|  | 762 | 1,724 |
|  | $(1,852)$ | 323 |
|  | 3,553 | $(14,747)$ |
|  | 1,218 | $(1,022)$ |
|  | $(1,878)$ | 1,562 |
|  | $(7,611)$ | $(15,366)$ |
|  | 107 | 396 |
|  | 573 | 2,351 |
|  | (181) | (143) |
|  | (276) | 250 |
|  | 47,561 | 30,036 |
|  | $(20,673)$ | $(16,984)$ |
|  | 131 | 315 |
|  | $(20,542)$ | $(16,669)$ |
|  | 114,500 | 66,500 |
|  | $(119,000)$ | $(84,000)$ |
|  | (791) | $(1,102)$ |
|  | $(7,910)$ | $(7,990)$ |
|  | 2,954 | 2,710 |
|  | (454) | (330) |
|  | $(6,693)$ | $(6,336)$ |
|  | $(17,394)$ | $(30,548)$ |
|  | 580 | $(1,171)$ |
|  | 10,205 | $(18,352)$ |
|  | 30,868 | 29,003 |
| \$ | 41,073 | 10,651 |

Cash provided by operating activities
Investing activities:

Capital expenditures
Proceeds from disposition of capital assets
Cash used for investing activities
Financing activities:
Borrowings under credit facilities
Repayments of credit facility borrowings
Repayments of other long-term debt
Common stock dividends paid
Issuance of common stock
Payroll tax paid to settle shares forfeited upon vesting of stock
Purchase of treasury stock
Cash used for financing activities
Effect of exchange rate changes on cash and cash equivalents
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

## QUANEX BUILDING PRODUCTS CORPORATION FREE CASH FLOW RECONCILIATION

(In thousands)
(Unaudited)
The following table reconciles the Company's calculation of Free Cash Flow, a non-GAAP measure, to its most directly comparable GAAP measure. The Company defines Free Cash Flow as cash provided by operating activities less capital expenditures.

Cash provided by operating activities
Capital expenditures
Free Cash Flow

| Three Months | uly 31, | Nine Months Ended July 31, |  |
| :---: | :---: | :---: | :---: |
| 2020 | 2019 | 2020 | 2019 |
| \$45,089 | \$29,893 | \$47,561 | \$30,036 |
| $(4,360)$ | $(3,962)$ | $(20,673)$ | $(16,984)$ |
| \$40,729 | \$25,931 | \$26,888 | \$13,052 |

## QUANEX BUILDING PRODUCTS CORPORATION

NON-GAAP FINANCIAL MEASURE DISCLOSURE
(In thousands, except per share data)
(Unaudited)

| Reconciliation of Adjusted Net Income and Adjusted EPS | Three Months Ended$\text { July 31, } 2020$ |  | Three Months Ended <br> July 31, 2019 |  |  |  | Nine Months Ended$\text { July 31, } 2020$ |  |  |  | Nine Months Ended <br> July 31, 2019 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Net Income | Diluted EPS | Net Income |  | Diluted EPS |  | Net Income |  | Diluted EPS |  | Net (Loss) Income |  | Diluted EPS |  |
| Net income (loss) as reported | \$ 10,833 | \$ 0.33 | \$ | 11,841 | \$ | 0.36 | \$ | 16,344 | \$ | 0.50 | s | $(15,782)$ | \$ | (0.48) |
| Reconciling items from below | 280 | 0.01 |  | 1,809 |  | 0.05 |  | 2,387 |  | 0.07 |  | 33,595 |  | 1.02 |
| Adjusted net income and adjusted EPS | \$ 11,113 | \$ 0.34 | \$ | 13,650 | \$ | 0.41 | \$ | 18,731 | \$ | 0.57 | \$ | 17,813 | \$ | 0.54 |
| Reconciliation of Adjusted EBITDA | Three Months Ended July 31, 2020 |  | Three Months Ended July 31, 2019 |  |  |  |  | Nine Months Ended July 31, 2020 |  |  |  | Nine Months Ended July 31, 2019 |  |  |

## Reconciliation

Net income
(loss) as reported Income tax expense
Other, net
\$ 10,833
\$ 11,841

$$
4,345
$$

Interest
expense
Depreciation
and
amortization
EBITDA
Reconciling items from below Adjusted
EBITDA
Reconciling Items

Net sales
Cost of sales

| 11,060 |
| ---: |
| 27,623 |

$\begin{array}{r}12,182 \\ \hline 31,292\end{array}$


Selling, general and administrative
Restructuring charges


Asset impairment charges
EBITDA
Depreciation and amortization Operating income (loss) Interest expense Other, net Income (loss) before income taxes Income tax expense Net income (loss)

Diluted earnings (loss) per share
0.33
$25,718 \quad(1,401)(1)$
94
(94) (2)
$62,818 \quad(1,398)(1)$
77,466


$(3,518)(1)$
(281) (2)
\$ $(15,782)$
5,926
(461)

7,614
$\begin{array}{r}37,158 \\ \hline 34,455\end{array}$



## Three months ended July 31, 2020

Net sales
Cost of sales
Gross Margin
Gross Margin \%
Selling, general and administrative
Restructuring charges
Depreciation and amortization
Operating income (loss)
Depreciation and amortization
EBITDA
Restructuring charges
Adjusted EBITDA
Adjusted EBITDA Margin \%
Three months ended July 31, 2019
Net sales
Cost of sales
Gross Margin
Gross Margin \%
Selling, general and administrative
Restructuring charges
Depreciation and amortization
Operating income (loss)
Depreciation and amortization
EBITDA
Transaction and advisory fees
Severance charges
Restructuring charges
Adjusted EBITDA
Adjusted EBITDA Margin \%

Nine months ended July 31, 2020
Net sales
Cost of sales
Gross Margin
Gross Margin \%
Selling, general and administrative
Restructuring charges
Depreciation and amortization
Operating income (loss)
Depreciation and amortization
EBITDA
Transaction and advisory fees
Executive severance charges
Restructuring charges
Adjusted EBITDA
Adjusted EBITDA Margin \%

## Nine months ended July 31, 2019

Net sales
Cost of sales
Gross Margin
Gross Margin \%
Selling, general and administrative
Restructuring charges
Depreciation and amortization
Asset impairment charges
Operating income (loss)
Depreciation and amortization
EBITDA
Asset impairment charges
Transaction and advisory fees
Severance related to reorganization
Restructuring charges
Adjusted EBITDA

| NA <br> Fenestration |  | $\begin{gathered} \text { EU } \\ \text { Fenestration } \\ \hline \end{gathered}$ |  | NA Cabinet Components |  | Unallocated Corp \& Other |  | Total |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| \$ | 122,386 | \$ | 38,265 | \$ | 51,925 | \$ | (480) | \$ | 212,096 |
|  | 92,639 |  | 25,845 |  | 44,218 |  | (275) |  | 162,427 |
|  | 29,747 |  | 12,420 |  | 7,707 |  | (205) |  | 49,669 |
|  | 24.3\% |  | 32.5\% |  | 14.8\% |  |  |  | 23.4\% |
|  | 11,922 |  | 4,748 |  | 4,634 |  | 669 |  | 21,973 |
|  | 71 |  | - |  | 2 |  | - |  | 73 |
|  | 5,371 |  | 2,307 |  | 3,264 |  | 118 |  | 11,060 |
|  | 12,383 |  | 5,365 |  | (193) |  | (992) |  | 16,563 |
|  | 5,371 |  | 2,307 |  | 3,264 |  | 118 |  | 11,060 |
|  | 17,754 |  | 7,672 |  | 3,071 |  | (874) |  | 27,623 |
|  | 71 |  | - |  | 2 |  | - |  | 73 |
| \$ | 17,825 | \$ | 7,672 | \$ | 3,073 | \$ | (874) | \$ | 27,696 |
|  | 14.6\% |  | 20.0\% |  | 5.9\% |  |  |  | 13.1\% |


| \$ | 136,259 | \$ | 44,326 | \$ | 58,689 | \$ | (813) | \$ | 238,461 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 101,693 |  | 30,708 |  | 49,389 |  | (433) |  | 181,357 |
|  | 34,566 |  | 13,618 |  | 9,300 |  | (380) |  | 57,104 |
|  | 25.4\% |  | 30.7\% |  | 15.8\% |  |  |  | 23.9\% |
|  | 11,950 |  | 6,038 |  | 4,484 |  | 3,246 |  | 25,718 |
|  | 94 |  | - |  | - |  | - |  | 94 |
|  | 6,578 |  | 2,213 |  | 3,258 |  | 133 |  | 12,182 |
|  | 15,944 |  | 5,367 |  | 1,558 |  | $(3,759)$ |  | 19,110 |
|  | 6,578 |  | 2,213 |  | 3,258 |  | 133 |  | 12,182 |
|  | 22,522 |  | 7,580 |  | 4,816 |  | $(3,626)$ |  | 31,292 |
|  | - |  | - |  | - |  | 250 |  | 250 |
|  | - |  | - |  | - |  | 1,151 |  | 1,151 |
|  | 94 |  | - |  | - |  | - |  | 94 |
| \$ | 22,616 | \$ | 7,580 | \$ | 4,816 | \$ | $(2,225)$ | \$ | 32,787 |
|  | $16.6 \%$ |  | $17.1 \%$ |  | 8.2\% |  |  |  | $13.7 \%$ |


| \$ | 341,432 | \$ | 104,230 | \$ | 152,634 | \$ | $(2,128)$ | \$ | 596,168 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 266,489 |  | 72,055 |  | 132,259 |  | $(1,217)$ |  | 469,586 |
|  | 74,943 |  | 32,175 |  | 20,375 |  | (911) |  | 126,582 |
|  | 21.9\% |  | 30.9\% |  | 13.3\% |  |  |  | 21.2\% |
|  | 34,962 |  | 15,990 |  | 13,468 |  | $(1,602)$ |  | 62,818 |
|  | 228 |  | - |  | 249 |  | - |  | 477 |
|  | 18,311 |  | 7,045 |  | 10,139 |  | 356 |  | 35,851 |
|  | 21,442 |  | 9,140 |  | $(3,481)$ |  | 335 |  | 27,436 |
|  | 18,311 |  | 7,045 |  | 10,139 |  | 356 |  | 35,851 |
|  | 39,753 |  | 16,185 |  | 6,658 |  | 691 |  | 63,287 |
|  | - |  | - |  | - |  | 55 |  | 55 |
|  | - |  | - |  | - |  | 1,343 |  | 1,343 |
|  | 228 |  | - |  | 249 |  | - |  | 477 |
| \$ | 39,981 | \$ | 16,185 | \$ | 6,907 | \$ | 2,089 | \$ | 65,162 |
|  | 11.7\% |  | 15.5\% |  | 4.5\% |  |  |  | 10.9\% |


| \$ | 360,654 | \$ | 121,203 | \$ | 175,377 | \$ | $(3,762)$ | \$ | 653,472 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 278,877 |  | 84,139 |  | 150,944 |  | $(2,668)$ |  | 511,292 |
|  | 81,777 |  | 37,064 |  | 24,433 |  | $(1,094)$ |  | 142,180 |
|  | 22.7\% |  | 30.6\% |  | 13.9\% |  |  |  | 21.8\% |
|  | 37,240 |  | 17,444 |  | 13,914 |  | 8,868 |  | 77,466 |
|  | 281 |  | - |  | - |  | - |  | 281 |
|  | 20,208 |  | 6,669 |  | 9,902 |  | 379 |  | 37,158 |
|  | - |  | - |  | 29,978 |  | - |  | 29,978 |
|  | 24,048 |  | 12,951 |  | $(29,361)$ |  | $(10,341)$ |  | $(2,703)$ |
|  | 20,208 |  | 6,669 |  | 9,902 |  | 379 |  | 37,158 |
|  | 44,256 |  | 19,620 |  | $(19,459)$ |  | $(9,962)$ |  | 34,455 |
|  | - |  | - |  | 29,978 |  | - |  | 29,978 |
|  | - |  | - |  | - |  | 1,217 |  | 1,217 |
|  | - |  | - |  | - |  | 2,301 |  | 2,301 |
|  | 281 |  | - |  | - |  | - |  | 281 |
| \$ | 44,537 | \$ | 19,620 | \$ | 10,519 | \$ | $(6,444)$ | \$ | 68,232 |

## QUANEX BUILDING PRODUCTS CORPORATION

SALES ANALYSIS
(In thousands)
(Unaudited)

| Three Months Ended |  |  |  | Nine Months Ended |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 31,2020 | July 31, 2019 |  | July 31,2020 |  | July 31, 2019 |  |
| \$ | 109,455 | \$ | 119,481 | \$ | 302,094 | \$ | 312,509 |
|  | 6,696 |  | 7,172 |  | 19,284 |  | 23,474 |
|  | 4,845 |  | 3,982 |  | 13,779 |  | 12,290 |
|  | 1,390 |  | 5,624 |  | 6,275 |  | 12,381 |
| \$ | 122,386 | \$ | 136,259 | \$ | 341,432 | \$ | 360,654 |
| \$ | 31,904 | \$ | 36,342 | \$ | 87,732 | \$ | 102,038 |
|  | 6,361 |  | 7,984 |  | 16,498 |  | 19,165 |
| \$ | 38,265 | \$ | 44,326 | \$ | 104,230 | \$ | 121,203 |
| \$ | 2,666 | \$ | 3,561 | \$ | 8,461 | \$ | 9,909 |
|  | 48,849 |  | 54,512 |  | 142,838 |  | 163,694 |
|  | 410 |  | 616 |  | 1,335 |  | 1,774 |
| \$ | 51,925 | \$ | 58,689 | \$ | 152,634 | \$ | 175,377 |
| \$ | (480) | \$ | (813) | \$ | $(2,128)$ | \$ | $(3,762)$ |
| \$ | (480) | \$ | (813) | \$ | $(2,128)$ | \$ | $(3,762)$ |
| \$ | 212,096 | \$ | 238,461 | \$ | 596,168 | \$ | 653,472 |

(1) Reflects reduction of $\$ 0.4$ million and $\$ 1.6$ million in revenue associated with foreign currency exchange rate impacts for the three and nine months ended July 31, 2020, respectively.

